LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 (LBRX)

Historical Holders from Q3 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001
Symbol
LBRX on Nasdaq
Shares outstanding
25,365,300
Price per share
$22.26
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
19,945,854
Total reported value
$314,944,399
% of total 13F portfolios
0%
Share change
+19,945,854
Value change
+$314,944,404
Avg buy value change
+0%
Number of holders
53
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 (LBRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Deep Track Capital, LP 15% 3,352,804 Deep Track Capital, LP 12 Sep 2025
TCG Crossover GP II, LLC 7.8% 1,745,015 TCG Crossover GP II, LLC 12 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 7.5% 1,675,000 RA Capital Management, L.P. 12 Sep 2025
Pontifax Management 4 G.P. (2015) Ltd. 6.3% 1,411,681 Pontifax Management 4 G.P. (2015) Ltd. 12 Sep 2025
Trails Edge Capital Partners, LP 5% $20,964,420 1,268,265 Trails Edge Capital Partners, LP 24 Dec 2025
Commodore Capital LP 5.5% 1,225,000 Commodore Capital LP 11 Sep 2025
BlackRock Portfolio Management LLC 5.9% $14,859,000 975,000 BlackRock Portfolio Management LLC 30 Sep 2025
As of 30 Sep 2025, LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 (LBRX) has 53 institutional shareholders filing 13F forms. They hold 19,945,854 shares. of 25,365,300 outstanding shares (79%) .

Top 25 institutional shareholders own 76% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Deep Track Capital, LP 13% 3,352,804 1.5% $52,940,775
RA CAPITAL MANAGEMENT, L.P. 7% 1,776,958 0.35% $28,058,167
TCG Crossover Management, LLC 6.9% 1,745,016 1.4% $27,553,803
Commodore Capital LP 5.9% 1,500,000 1.2% $23,685,000
Logos Global Management LP 4.5% 1,130,000 1.8% $17,842,700
JPMORGAN CHASE & CO 4.1% 1,032,603 0% $16,304,801
BlackRock, Inc. 3.8% 975,000 0% $15,395,251
Balyasny Asset Management L.P. 3.8% 968,274 0.03% $15,289,046
Vivo Capital, LLC 3.2% 800,000 1% $12,632,000
JENNISON ASSOCIATES LLC 2.9% 739,040 0.01% $11,669,441
Nantahala Capital Management, LLC 2.7% 675,000 0.66% $10,658,250
Alyeska Investment Group, L.P. 2.7% 675,000 0.03% $10,658,250
CITADEL ADVISORS LLC 2.1% 539,370 0.01% $8,516,653
MILLENNIUM MANAGEMENT LLC 2.1% 538,169 0.01% $8,497,689
Soleus Capital Management, L.P. 1.6% 400,000 0.34% $6,316,000
FMR LLC 1.5% 369,100 0% $5,828,089
WELLINGTON MANAGEMENT GROUP LLP 1.4% 344,657 0% $5,442,134
GOLDMAN SACHS GROUP INC 1.4% 343,523 0% $5,424,228
Nan Fung Group Holdings Ltd 1.2% 300,000 7.9% $4,737,000
PRICE T ROWE ASSOCIATES INC /MD/ 1.1% 282,644 0% $4,463,000
MARSHALL WACE, LLP 1% 255,526 0% $4,034,755
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.79% 200,000 0.01% $3,158,000
BAKER BROS. ADVISORS LP 0.79% 200,000 0.02% $3,158,000
Integral Health Asset Management, LLC 0.39% 100,000 0.12% $1,579,000
AMERIPRISE FINANCIAL INC 0.31% 77,450 0% $1,222,936

Institutional Holders of LB PHARMACEUTICALS INC - Common Stock, par value $0.0001 (LBRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 6,448 $143,312 +$143,312 2,225.57% 2
2025 Q3 19,945,854 $314,944,399 +$314,944,404 1,579% 53